Drug Trial Radar · NCT03180840
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 10, 2017
Primary completion
Aug 1, 2020
Study completion Aug 1, 2020
Sponsor
- Lead sponsor
- ProtalixIndustry
- Sponsor type
- Industry
- Collaborators
- Chiesi Farmaceutici S.p.A.
- First posted
- Jun 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label switchover study will assess the safety, efficacy, and pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg administered every 4 weeks for 52 weeks in Fabry patients previously treated with ERT: agalsidase alfa or agalsidase beta for at least 3 years. Safety and efficacy exploratory endpoints will be evaluated throughout the study period and pharmacokinetics will be obtained on Day 1 and Week 52.
Conditions
- Fabry Disease
Interventions
Pegunigalsidase alfaBiological
Pegunigalsidase alfa 2 mg/kg every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse Events (TEAE) as Assessed by CTCAE v4.03Time frame: Month 12
Locations
14 sites in 7 countries. Site status is shown where the registry gives one.
UAB Medicine
Birmingham, Alabama
Emory University School of Medicine
Atlanta, Georgia
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Infusion Associates
Grand Rapids, Michigan
Institute of Metabolic Disease
Dallas, Texas
University of Utah Hospital & Clinics
Salt Lake City, Utah
O & O Alpan
Fairfax, Virginia
UZ Antwerpen
Edegem, Belgium
Fakultní poliklinika Všeobecné fakultní nemocnice v Praze
Prague, Czechia
Rigshospitalet
Copenhagen, Denmark
Azienda Ospedaliera Universitaria "Federico II"
Naples, Italy
Helse Bergen HF Haukeland Universitetssykehus
Bergen, Norway
Addenbrooke's Hospital
Cambridge, United Kingdom
The Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.